Would you give one breath if you could detect lung cancer and other diseases?
Introducing OneBreath™
A unique technology platform developed by Breath Diagnostics to quantitatively analyze organic compounds in a single breath to detect lung cancer and other diseases.1
Our highly portable system will be readily available to patients through medical providers.1
In contrast to a Low-Dose CT Scan, OneBreath is a quicker and easier way of lung cancer diagnosis. We are currently enrolling patients for our 2nd generation system Pilot Study.
Breath Collection
Patients provide one complete breath via a unique collection system in less than 30 seconds.
Breath Processing and Analysis
In a simple automated process, the OneBreath™ micro-reactor captures the organic compounds contained in the breath. Once captured, the samples is analyzed in our laboratories.
Get Results
Results will be available within 3-4 business days.
Why OneBreath™?
OneBreath™ provides a safe, convenient, and inexpensive way to identify lung cancer in at risk patients, before they know they have a problem.1
Accurate Results
OneBreath™ detects lung cancer with fewer false positives and higher specificity than a low-dose CT scan.
Accessible
The OneBreath™ system increases access to potentially life-saving lung cancer screenings by being portable enough for use in a physician's office or local pharmacy.
Affordable
The OneBreath™ technology platform demonstrates a lower false positive rate versus CT scans, reducing the number of unnecessary follow-up diagnostic procedures.
Easy to Use
The simplicity of the OneBreath™ system provides the potential to enhance screening compliance due to the fact that only a single breath is required.
Research & Publications
It’s Official: Meet 4 of the Country’s Most Impressive Healthcare Startups
A quartet of companies on Wednesday were selected among the 44 companies that presented at MedCity INVEST, MedCity News' healthcare investing conference.
News
April 13, 2016
High Sensitivity for Lung Cancer Detection Using Analysis of Exhaled Carbonyl Compounds
Screening using a low-dose CT scan is associated with high cost, repeated radiation exposure, and low accrual. The high sensitivity, convenience, and low cost of breath analysis for carbonyl cancer markers suggests that it has the potential to become a primary screening modality for lung cancer.
Research
August 31, 2015
Testimonials
To the promise of breath based lung cancer diagnostics and what Breath diagnostics could offer patients
"Technology like OneBreath has so much potential for improving and saving lives."
Dr. Kevin Gardner
Executive VP Research and Innovation, University of Louisville
OneBreath™ by Breath Diagnostics
OneBreath™ may save your life.
Contact us to discover the future of lung cancer screening or click below to learn more.1
